Literature DB >> 17053453

Mesenchymal stromal cells.

Armand Keating1.   

Abstract

PURPOSE OF REVIEW: Our understanding of the biology and properties of mesenchymal stem cells or multipotent mesenchymal stromal cells has expanded dramatically over the last 3 years and is likely to have an impact on clinical practice in the near future, making a review of this topic both timely and relevant RECENT
FINDINGS: Recommendations regarding nomenclature and the definition of mesenchymal stromal cells have been proposed, a rapidly dividing population within the mesenchymal stromal cell compartment has been better defined and the ability of these cells to exhibit characteristics of cells from a variety of lineages has been extended. The notion that tissue repair with mesenchymal stromal cells is related to transdifferentiation has been re-evaluated and, for the myocardium at least, may be due rather to a paracrine mechanism. The most dramatic developments have been in identifying some of the complex mechanisms underlying the immunosuppressive and nonimmunogenic properties of mesenchymal stromal cells which have important implications for the management of conditions like acute graft-versus-host disease.
SUMMARY: Mesenchymal stromal cells are a biologically important cell population that are able to support hematopoiesis, can differentiate along mesenchymal and nonmesenchymal lineages in vitro, are capable of suppressing alloresponses and appear to be nonimmunogenic. These properties suggest emerging roles for mesenchymal stromal cells in cell therapy.

Entities:  

Mesh:

Year:  2006        PMID: 17053453      PMCID: PMC3365862          DOI: 10.1097/01.moh.0000245697.54887.6f

Source DB:  PubMed          Journal:  Curr Opin Hematol        ISSN: 1065-6251            Impact factor:   3.284


  23 in total

1.  Nonhematopoietic mesenchymal stem cells: what are they?

Authors:  E M Horwitz; A Keating
Journal:  Cytotherapy       Date:  2000       Impact factor: 5.414

2.  Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells.

Authors:  Katarina Le Blanc; Ida Rasmusson; Berit Sundberg; Cecilia Götherström; Moustapha Hassan; Mehmet Uzunel; Olle Ringdén
Journal:  Lancet       Date:  2004-05-01       Impact factor: 79.321

3.  Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy.

Authors:  O N Koç; S L Gerson; B W Cooper; S M Dyhouse; S E Haynesworth; A I Caplan; H M Lazarus
Journal:  J Clin Oncol       Date:  2000-01       Impact factor: 44.544

4.  The SH-3 and SH-4 antibodies recognize distinct epitopes on CD73 from human mesenchymal stem cells.

Authors:  F Barry; R Boynton; M Murphy; S Haynesworth; J Zaia
Journal:  Biochem Biophys Res Commun       Date:  2001-11-30       Impact factor: 3.575

5.  The monoclonal antibody SH-2, raised against human mesenchymal stem cells, recognizes an epitope on endoglin (CD105).

Authors:  F P Barry; R E Boynton; S Haynesworth; J M Murphy; J Zaia
Journal:  Biochem Biophys Res Commun       Date:  1999-11       Impact factor: 3.575

6.  Precursors for fibroblasts in different populations of hematopoietic cells as detected by the in vitro colony assay method.

Authors:  A J Friedenstein; U F Deriglasova; N N Kulagina; A F Panasuk; S F Rudakowa; E A Luriá; I A Ruadkow
Journal:  Exp Hematol       Date:  1974       Impact factor: 3.084

7.  Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues.

Authors:  A J Friedenstein; K V Petrakova; A I Kurolesova; G P Frolova
Journal:  Transplantation       Date:  1968-03       Impact factor: 4.939

8.  Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome (MPS-IH).

Authors:  O N Koç; J Day; M Nieder; S L Gerson; H M Lazarus; W Krivit
Journal:  Bone Marrow Transplant       Date:  2002-08       Impact factor: 5.483

9.  Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors.

Authors:  Matus Studeny; Frank C Marini; Richard E Champlin; Claudia Zompetta; Isaiah J Fidler; Michael Andreeff
Journal:  Cancer Res       Date:  2002-07-01       Impact factor: 12.701

10.  Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone.

Authors:  Edwin M Horwitz; Patricia L Gordon; Winston K K Koo; Jeffrey C Marx; Michael D Neel; Rene Y McNall; Linda Muul; Ted Hofmann
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-25       Impact factor: 11.205

View more
  107 in total

1.  Human embryonic stem cell-derived mesenchymal stromal cells.

Authors:  Peiman Hematti
Journal:  Transfusion       Date:  2011-11       Impact factor: 3.157

2.  ApoA1: mimetic peptide reverses adipocyte dysfunction in vivo and in vitro via an increase in heme oxygenase (HO-1) and Wnt10b.

Authors:  Luca Vanella; Ming Li; DongHyun Kim; Giuseppe Malfa; Lars Bellner; Tomoko Kawakami; Nader G Abraham
Journal:  Cell Cycle       Date:  2012-02-15       Impact factor: 4.534

Review 3.  Immune regulatory cells in umbilical cord blood and their potential roles in transplantation tolerance.

Authors:  Young-June Kim; Hal E Broxmeyer
Journal:  Crit Rev Oncol Hematol       Date:  2010-08-19       Impact factor: 6.312

Review 4.  Multidisciplinary approaches to stimulate wound healing.

Authors:  Rita Businaro; Mariangela Corsi; Tania Di Raimo; Sergio Marasco; Debra L Laskin; Bruno Salvati; Raffaele Capoano; Serafino Ricci; Camilla Siciliano; Giacomo Frati; Elena De Falco
Journal:  Ann N Y Acad Sci       Date:  2016-07-19       Impact factor: 5.691

Review 5.  Stem cells and cell therapies in lung biology and lung diseases.

Authors:  Daniel J Weiss; Jay K Kolls; Luis A Ortiz; Angela Panoskaltsis-Mortari; Darwin J Prockop
Journal:  Proc Am Thorac Soc       Date:  2008-07-15

6.  Identification and isolation of small CD44-negative mesenchymal stem/progenitor cells from human bone marrow using elutriation and polychromatic flow cytometry.

Authors:  Sean R R Hall; Yajuan Jiang; Elizabeth Leary; Greg Yavanian; Sarah Eminli; David W O'Neill; Wayne A Marasco
Journal:  Stem Cells Transl Med       Date:  2013-07-11       Impact factor: 6.940

7.  Intranasal delivery of central nervous system-retargeted human mesenchymal stromal cells prolongs treatment efficacy of experimental autoimmune encephalomyelitis.

Authors:  Moa Fransson; Elena Piras; Hao Wang; Joachim Burman; Ida Duprez; Robert A Harris; Katarina LeBlanc; Peetra U Magnusson; Eva Brittebo; Angelica S I Loskog
Journal:  Immunology       Date:  2014-07       Impact factor: 7.397

8.  Mesenchymal stromal cells mediate Aspergillus hyphal extract-induced allergic airway inflammation by inhibition of the Th17 signaling pathway.

Authors:  Melissa J Lathrop; Elice M Brooks; Nick R Bonenfant; Dino Sokocevic; Zachary D Borg; Meagan Goodwin; Roberto Loi; Fernanda Cruz; Chad W Dunaway; Chad Steele; Daniel J Weiss
Journal:  Stem Cells Transl Med       Date:  2014-01-16       Impact factor: 6.940

9.  Stem cells from in- or outside of the heart: isolation, characterization, and potential for myocardial tissue regeneration.

Authors:  Willy A Noort; Joost P G Sluijter; Marie-Jose Goumans; Steven A J Chamuleau; Pieter A Doevendans
Journal:  Pediatr Cardiol       Date:  2009-01-30       Impact factor: 1.655

10.  Oct4 expression is not required for mouse somatic stem cell self-renewal.

Authors:  Christopher J Lengner; Fernando D Camargo; Konrad Hochedlinger; G Grant Welstead; Samir Zaidi; Sumita Gokhale; Hans R Scholer; Alexey Tomilin; Rudolf Jaenisch
Journal:  Cell Stem Cell       Date:  2007-10-11       Impact factor: 24.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.